|Home | About | Journals | Submit | Contact Us | Français|
The integrity of endothelial monolayer is a sine qua non for vascular homeostasis and maintenance of tissue fluid balance. However, little is known about the signaling pathways regulating regeneration of the endothelial barrier following inflammatory vascular injury.
Employing genetic and pharmacological approaches, we demonstrated that endothelial regeneration selectively requires activation of p110γPI3K signaling, which thereby mediates the expression of the endothelial reparative transcription factor FoxM1. We observed that FoxM1 induction in the pulmonary vasculature was inhibited in mice treated with p110γ-selective inhibitor and in Pik3cg−/− mice following LPS challenge. Pik3cg−/− mice exhibited persistent lung inflammation induced by sepsis and sustained increase in vascular permeability. Restoration of expression of either p110γ or FoxM1 in pulmonary endothelial cells of Pik3cg−/− mice restored endothelial regeneration and normalized the defective vascular repair program. We also observed diminished expression of p110γ in pulmonary vascular endothelial cells of ARDS patients, suggesting that impaired p110γ-FoxM1 vascular repair signaling pathway is a critical factor in persistent leaky lung microvessels and edema formation in the disease.
We identify p110γ as the critical mediator of endothelial regeneration and vascular repair following sepsis-induced inflammatory injury. Thus, activation of p110γ-FoxM1 endothelial regeneration may represent a novel strategy for the treatment of inflammatory vascular diseases.
The integrity of endothelial monolayer is a sine qua non for vascular homeostasis and maintenance of tissue fluid balance.1, 2 The key function of the endothelial barrier is to maintain fluid balance between the blood plasma and interstitium.3, 4 Endothelial injury results in most of the complications associated with inflammation: increased vascular permeability to protein, diapedesis of erythrocytes and transmigration of inflammatory cells, tissue edema and microthrombi formation.5–7 In acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), vascular endothelial injury leads to extravasation of neutrophils and monocytes and accumulation and intractability of protein-rich edema.8–10 After vascular injury, repair of the endothelial monolayer through activation of intrinsic endothelial repair programs is a prerequisite for restoring vascular homeostasis.11–14
Endothelial regeneration occurs due to endothelial proliferation and re-annealing of endothelial junctions to form the characteristic restrictive endothelial barrier.11, 15–17 We showed that Forkhead box M1 (FoxM1), belonging to fox family of transcriptional factors sharing homology in winged helix DNA-binding domains,18 is required for vascular endothelial regeneration.11 FoxM1 mediated G1/S and G2/M transition secondary to transcriptional control of cell cycle progression genes.19–22 FoxM1 expression was upregulated in endothelial cells (ECs) only during the repair phase following vascular injury induced by lipopolysaccharide (LPS).11 In mice with EC-restricted disruption of FoxM1, endothelial barrier recovery following LPS challenge was severely impaired due to defective EC proliferation11 and re-annealing of endothelial adherens junctions.15
Phosphoinositide 3-kinases (PI3Ks) are cellular lipid kinases that phosphorylate the 3 position hydroxyl group of the inositol ring of phosphatidylinositol to generate the lipid second messenger phosphatidylinositol 3,4,5-triphosphate.23–25 Studies have focused on class I PI3K comprising the class IA (p110α, β, and δ) and class IB (p110γ, encoded by Pik3cg) isoforms. Class IA kinases forming a complex with SH2-conatining regulatory p85-related subunits are in general activated through receptor tyrosine kinases whereas class IB, p110γ is activated by G protein-coupled receptors (GPCR) through its regulatory subunit p101 or p84 and G-protein subunits.24,25 p110β is also activated by GPCR signaling in p110γ-deficient cells.26 p110γ is expressed in leukocytes and at low levels in ECs and smooth muscle cells. In neutrophils, eosinophils and macrophages, p110γ mediates chemokine-induced migration of these cells.27, 28 It has been shown that p110γ plays an important role in the initial inflammatory responses (at 1 or 6h post-challenge) to sepsis challenge via regulating neutrophil recruitment and migration.29, 30 However, little is known about the role of p110γ in regulating endothelial regeneration and vascular repair during the repair phase. Here we focused on the fundamental role of endothelial p110γ based on our observation that p110γ expression was markedly reduced in pulmonary vascular ECs of ARDS patients (see Results). In the mouse model of endotoxemia, we demonstrated that p110γ deficiency severely impaired vascular repair following lipopolysaccharide (LPS) challenge and that restoration of endothelial expression of either p110γ or FoxM1 normalized defective endothelial regeneration in Pik3cg−/− mice. Thus, selectively targeting p110γ to promote FoxM1-mediated vascular repair represents a novel therapeutic strategy for the treatment of inflammatory vascular diseases such as acute lung injury.
Pik3cg−/− mice were obtained from Dr. Joseph Penninger (Amgen Institute, Canada).29,31 FoxM1 transgenic mice were obtained from Dr. Robert H. Costa at the University of Illinois College of Medicine.20 Littermate WT mice (C57BL/6 background) were used as controls. All mice were bred and maintained in the Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facilities at the University of Illinois at Chicago according to National Institutes of Health guidelines. All animal experiments were performed in accordance with protocols approved by the University of Illinois at Chicago Animal Care and Use Committee.
Human lung tissues were obtained from ARDS patients (n = 6) and unused donor lungs (n=8) under supervision of Kurt Albertine. Informed consents and approval from Ethics Committee of the University of Utah (IRB #5632) were obtained prior to tissue collection.
Data are expressed as mean ± SD. Statistical significance was determined by one-way ANOVA with a Games-Howell post hoc analysis for multiple group comparisons. Two-group comparisons were analyzed by the two-tailed unpaired Student’s t test or Mann-Whitney (nonparametric) test depending on the data distribution. Statistical analysis of the mortality study was performed with the Log–rank (Mantel-Cox) test. The P-values are two-sided. P < 0.05 denoted the presence of a statistically significant difference.
An expanded Materials and Methods section containing detailed description of induction of polymicrobial sepsis, lung transvascular albumin flux assessment, scanning electron microscopy, intravital microscopy, myeloperoxidase assay, histology and imaging, in situ cell proliferation and apoptosis assay, primary cultures of human lung microvascular ECs, molecular analysis, liposome-mediated transduction of cDNA into mouse lung vascular ECs is provided in the online-only Data Supplement.
We first used the pan-PI3K inhibitor wortmannin to determine the role of PI3K signaling in regulating FoxM1 expression in the pulmonary vasculature following inflammatory injury. At 12h post-LPS challenge, WT mice were treated with wortmannin (i.p., 0.05mg/kg BW, every 12h) or the vehicle DMSO. There was little FoxM1 induction at 24h post-LPS challenge in lungs of either DMSO- or wortmannin-treated mice, whereas FoxM1 mRNA expression in DMSO-treated lungs was upregulated at 48 and 72h post-LPS (Figure 1A). This time course directly paralleled the time course of lung vascular repair seen in this model.11 Western blotting demonstrated decreased FoxM1 protein expression in the wortmannin-treated mice (Figure 1B).
To identify the PI3K isoform mediating FoxM1 upregulation, mice were treated at 12h post-LPS challenge with either PI-103, a p110α inhibitor,32 or AS-605240, a p110γ inhibitor.33 Quantitative real-time RT-PCR (QRT-PCR) analysis showed that only p110γ inhibition decreased FoxM1 expression at 72h post-LPS (Figure 1C). Using lungs from Pik3cg−/− mice, we confirmed that FoxM1 expression was inhibited post-LPS in these lungs (Figure 1D). These data demonstrate that FoxM1 induction in the pulmonary vasculature following LPS challenge selectively requires the p110γPI3K isoform.
We next determined alterations in vascular permeability by assessing pulmonary transvascular flux of Evans blue-conjugated albumin (EBA).34 EBA flux increased 3–4 fold and peaked within 24h post-LPS challenge in Pik3cg−/− lungs similar to WT lungs (Figure 2A). EBA flux in WT lungs returned to basal levels at 60h post-LPS indicating full recovery whereas Pik3cg−/− lungs exhibited persistent vascular leakiness indicating defective vascular repair. Lung microvascular integrity was also examined by scanning electron microscopy after filling vessels with the tracer methyl methacrylate. At 60h post-LPS challenge, WT lungs had minimal tracer extravasation as seen in WT and Pik3cg−/− lungs basally whereas Pik3cg−/− lungs exhibited striking leakage (Figure 2B) consistent with the albumin permeability data above. TUNEL staining also revealed similar rate of apoptosis in Pik3cg−/− lungs compared to WT at 24h post-LPS challenge (Supplemental Figure 1), further demonstrating similar injury in Pik3cg−/− and WT lungs induced by LPS challenge. Thus, the critical difference is impaired vascular repair in Pik3cg−/− lungs.
Lungs from Pik3cg−/− mice also showed greater perivascular infiltration of leukocytes at 48h post-LPS challenge compared to WT lungs (Figure 3A and 3B). Lung myeloperoxidase (MPO) activity11 showed similar neutrophil infiltration in WT and Pik3cg−/− lungs during the injury phase up to 24h post-LPS except p110γ deficiency induced an early decrease of neutrophil infiltration at 2h post-LPS (Figure 3C and Supplemental Figure 2). By 48h post-LPS challenge, MPO activity in WT lungs returned to basal level whereas MPO activity in Pik3cg−/− lungs remained elevated (Figure 3C). QRT-PCR analysis demonstrated increased expression of ICAM-1 and pro-inflammatory cytokines as well as iNOS at 48h post-LPS in Pik3cg−/− lungs (Figure 3, D–G) consistent with persistence of lung inflammation in Pik3cg−/− mice. Given that p110γ deficiency itself affects the initial neutrophil recruitment following LPS challenge (Supplemental Figure 2), we treated WT mice with the p110γ inhibitor at 12h post-LPS challenge. As shown in Supplemental Figure 3, p110γ inhibitor-treated mice exhibited similar lung vascular permeability and inflammation responses at 24h post-LPS challenge as the controls. However, the p110γ inhibitor-treated mice showed greater EBA extravasation and MPO activity at 48h post-LPS challenge, supporting the role of p110γ deficiency in impairing the lung vascular repair program.
To address at the genetic level the function of p110γ upstream of FoxM1, we generated a mouse model with genetic deletion of Pik3cg and transgenic expression of human FOXM1 (Pik3cg−/−/FOXM1Tg) (Pg−/−/Tg). FoxM1 transgenic mice in which FOXM1 expression was under control of the Rosa promoter20 were bred into the genetic background of Pik3cg−/−. Pg−/−/Tg lungs showed increased FoxM1 expression at basal (Figure 2C) and 72h post-LPS challenge (Supplemental Figure 4). Pg−/−/Tg mice exhibited the same maximal increases in vascular permeability as WT and Pik3cg−/− lungs at 18h post-LPS (Figure 2A). However, in contrast to Pik3cg−/− lungs, vascular permeability in Pg−/−/Tg mouse lungs during the repair phase was markedly reduced; that is, Pg−/−/Tg mouse lungs showed similar vascular leakage as WT mouse lungs at 48, 60, and 72h post-LPS challenge (Figure 2A). Scanning electron microscopy also demonstrated normal vascular barrier integrity in Pg−/−/Tg mouse lungs at 60h post-LPS as seen in WT lungs (Figure 2B).
We also performed real-time intravital microscopy to assess vascular permeability in live animals. FITC-conjugated dextran was injected through tail vein and cremaster muscle was then exteriorized onto an intravital microscopy tray to image the vascular permeability of cremaster muscle venules. As shown in Figure 2D and 2E, Pik3cg−/− mice exhibited similar basal permeability as WT and Pg−/−/Tg mice. However, at 48h post-LPS challenge, Pik3cg−/− mice exhibited marked increase of vascular permeability compared to WT mice, whereas Pg−/−/Tg mice exhibited similar vascular permeability as seen in WT mice. These data suggest p110γ-mediated vascular repair via FoxM1 is a generalized process following inflammatory vascular injury.
To determine whether persistent lung inflammation in Pik3cg−/− mice was also the result of decreased FoxM1 expression, we assessed leukocyte infiltration and MPO activity in Pg−/−/Tg mice. H & E staining revealed that perivascular infiltration of leukocytes in Pik3cg−/− mouse lungs during the repair phase (e.g., 48h post-LPS) was normal in Pg−/−/Tg mouse lungs, and similar to WT lungs (Figure 3A and 3B). During the lung vascular injury and inflammation phase (up to 24h) post-LPS, Pg−/−/Tg mouse lungs exhibited similar MPO activity as WT and Pik3cg−/− mouse lungs (Figure 3C and Supplemental Figure 2). In contrast to Pik3cg−/− mouse lungs, MPO activity during the repair phase in Pg−/−/Tg lungs returned to basal levels (Figure 3C). Elevated expression levels of ICAM-1 and various pro-inflammatory mediators seen in Pik3cg−/− mouse lungs at 48h post-LPS were also restored in Pg−/−/Tg mouse lungs (Figure 3, D–G).
We next determined whether p110γ-induced FoxM1 expression was required for EC proliferation as measured by BrdU incorporation.11 As shown in Figure 4A and 4B, WT mouse lungs exhibited marked increase in cell proliferation at 72h post-LPS compared to WT lungs at basal as also previously shown.11 However, we observed decreased cell proliferation in Pik3cg−/− mouse lungs, which was the result of reduced EC proliferation as demonstrated by co-localization of EC markers vWF/CD31 and BrdU immunostaining. This defective response was restored in Pik3cg−/−/Tg mouse lungs.
To address the basis of decreased endothelial proliferation in Pik3cg−/− lungs, we determined expression of FoxM1 target genes essential for cell cycle progression. QRT-PCR analysis showed that expression of Cdc25C, Cyclin B1 and Cyclin A2 was upregulated in WT lungs during the repair phase at 48 and 72h post-LPS challenge but not in Pik3cg−/− lungs (Figure 4, C–E). Overexpression of FoxM1 in Pg−/−/Tg lungs however significantly increased the expression of these genes indicating that FoxM1 is the effector of p110γ-mediated EC proliferation in vivo.
We next employed liposome-mediated gene transduction15 to address whether forced expression of p110γ in pulmonary vascular ECs of Pik3cg−/− mice will reverse the defective vascular repair. Transduction of plasmid DNA expressing human p110γ under the control of the 3.5kb CDH5 (encoding VE-cadherin) promoter35 restored p110γ expression in lung ECs of these mice (Figure 5A and Supplemental Figure 5). In Pik3cg−/− mouse lungs at 60h post-LPS challenge, restored endothelial expression of p110γ markedly reduced pulmonary transvascular EBA flux and MPO activity compared to control Pik3cg−/− mouse lungs (Figure 5B and 5C). These lungs also expressed low levels of pro-inflammatory molecules during vascular repair phase at 60h post-LPS challenge in contrast to control Pik3cg−/− lungs transduced with empty vector DNA (Figure 5, D–E). However, restored p110γ expression in ECs of Pik3cg−/− lungs didn’t normalize the initial defective recruitment and migration of neutrophils at 2h post-LPS whereas transplantation of WT bone marrow cells to Pik3cg−/− mice resulted in normal neutrophil infiltration (Supplemental Figure 6). Thus, defective vascular repair in Pik3cg−/− mice is ascribed to diminished expression of p110γ in ECs whereas impaired neutrophil recruitment and migration during the early response to LPS challenge is owing to p110γ deficiency in neutrophils.
We next addressed whether restoration of endothelial p110γ expression in Pik3cg−/− mouse lungs induced FoxM1 expression and thereby endothelial regeneration after injury. In the Pik3cg−/− lungs in which p110γ had been restored in ECs, FoxM1 mRNA expression was induced similarly in WT lungs (Figure 5F). The downstream targets of FoxM1 responsible for cell cycle progression Cdc25C and Cyclin B1 were also upregulated in these lungs in contrast to the control Pik3cg−/− mouse lungs (Figure 5G and 5H). BrdU labeling demonstrated normal proliferation rate in the mouse lung ECs in which p110γ was introduced (Figure 5I and Supplemental Figure 7). These data demonstrate that endothelial expression of p110γ is required for FoxM1 induction and resulting endothelial regeneration following inflammatory vascular injury.
Given that FoxM1 is ubiquitously expressed in all cell types in Pg−/−/Tg mice, it is unclear whether the normalized endothelial regeneration and vascular repair is ascribed to FoxM1 expression in ECs or other cells through a parallel pathway. To address this important question, we employed a similar liposome-mediated gene transduction approach to restore FoxM1 expression specifically in lung ECs of Pik3cg−/− mice. Plasmid DNA expressing human FOXM1 under the control of CDH5 promoter was transduced in Pik3cg−/− lungs at 12h post-LPS challenge. Liposome-mediated expression of FoxM1 in Pik3cg−/− lung ECs (Figure 6A) resulted in normalized vascular repair response (Figure 6B and 6C). Pulmonary transvascular EBA flux and MPO activity were markedly reduced in Pik3cg−/− mouse lungs transduced with the FOXM1 plasmid, in contrast to non-FOXM1-transduced Pik3cg−/− lungs (Figure 6B and 6C). Together, these data in Figures 5 and and66 demonstrate that p110γ and FoxM1 are acting specifically in ECs in vivo to mediate endothelial regeneration and vascular repair.
We next addressed the pathophysiological relevance of these findings using the mouse cecal ligation and puncture (CLP) model, which causes polymicrobial septicemia accompanied by ALI. CLP similarly increased pulmonary vascular EBA flux at 24h post-challenge in WT, Pik3cg−/−, and Pg−/−/Tg mice (Figure 7A). However during the recovery phase at 48 and 72h post-CLP, EBA flux was markedly decreased in both WT and Pg−/−/Tg mouse lungs whereas Pik3cg−/− mouse lungs showed persistent increase (Figure 7A). Pik3cg−/− mouse lungs also showed impaired resolution of neutrophilic inflammation (assessed by MPO activity) (Figure 7B). Strikingly, Pik3cg−/− mice exhibited a greater mortality rate (60%). Similar to WT mice, less than 20% of Pg−/−/Tg mice died at the same period (Figure 7C).
To further address the clinical relevance of these observations in mice to the pathogenesis of ARDS in patients, we examined p110γ protein levels in lung sections from ARDS patients.36 As shown in Figure 7D and 7E, p110γ expression is markedly diminished in pulmonary vascular ECs from ARDS patients.
Different from other class I PI3K isoforms, p110γ is GPCR-dependent23–25. To determine which GPCR signaling activates p110γ and thereby induces FoxM1 expression in ECs, human lung microvascular ECs were treated with two well-known GPCR agonists SDF-1α (also called CXCL12) and sphingosine-1-phosphate, respectively. As shown in Figure 8A, SDF-1α induced FoxM1 expression in ECs. However, sphingosine-1-phosphate had no effect on FoxM1 expression (data not shown). Inhibition of p110γ but not p110β blocked SDF-1α-induced FoxM1 expression (Figure 8B).
Next we examined the signaling mediator downstream of p110γ. FoxO is inactivated by PI3K through phosphorylation-induced translocation out of nucleus36. As shown in Figure 8C, SDF-1α treatment induced FoxO1 translocation out of nucleus in a p110γ-dependent manner. Thus, we determined whether FoxO1 is a negative regulator of p110γ-dependent FoxM1 expression. Co-treatment with p110γ inhibitor and FoxO1-selective inhibitor AS184285637 reversed p110γ inhibition-mediated blockade of SDF-1α-induced FoxM1 expression whereas FoxO1 activator psammaphysene A which inhibits FoxO1 nuclear export38 inhibited SDF-1α-induced FoxM1 expression (Figure 8D).
To determine whether SDF-1α was induced in mouse lungs responsible for activation of p110γ in vivo, we examined SDF-1α mRNA expression in WT mouse lungs at different times following LPS challenge. SDF-1α was initially decreased and then returned to basal levels at 24h post-LPS challenge (Figure 8E). Importantly, SDF-1α expression was markedly induced at 48h post-LPS challenge during the recovery phase (Figure 8E), indicating the important role of SDF-1α signaling-activated p110γ in mediating FoxM1 expression and thereby endothelial regeneration following inflammatory vascular injury (Figure 8F).
We have identified a novel function of p110γ expressed in ECs in mediating endothelial regeneration and vascular repair through the activation of the endothelial reparative transcription factor FoxM1. We showed that endothelial p110γ activation following endotoxemia-induced vascular injury was required for FoxM1 activation and the resulting repair of the endothelial barrier. We also identified SDF-1α as a critical agonist to activate the GPCR-dependent p110γPI3K and thereby induces FoxM1 expression in ECs through inactivation of FoxO1. The finding that p110γ expression was reduced in pulmonary vascular ECs of ARDS patients, suggests that impaired p110γ function itself is a fundamental determinant of persistent lung vascular leakiness and the poorly resolving inflammation seen in these patients.
We have shown previously role of FoxM1 in ECs in mediating endothelial regeneration and vascular repair.11, 15 As little is known about the upstream signaling mechanisms mediating FoxM1 induction in ECs, here we focused on the PI3K isoform p110γ that was found to have reduced expression in pulmonary vascular ECs of ARDS patients. Several lines of evidence in the present study support the requirement of endothelial p110γ in mediating FoxM1 expression and resultant vascular repair. Treatment of mice with the p110γ-inhibitor AS-605240 at 12h post-LPS challenge (i.e., after the induction of lung inflammation and vascular injury) markedly decreased FoxM1 expression in mouse lungs and failed to restore vascular integrity. In addition, FoxM1 activation was blocked in Pik3cg−/− mouse lungs in response to LPS challenge and this was accompanied by persistent lung inflammation and vascular injury. Endothelial-specific expression of p110γ in lung vessels of Pik3cg−/− mouse was sufficient to induce FoxM1 expression and activate vascular repair. These data collectively suggest that activation of endothelial p110γ mediates FoxM1 expression in ECs and thereby activates the endothelial regeneration and vascular repair program following sepsis-induced inflammatory vascular injury. Consistent with our observation, previous study has shown that PI3K signaling is involved in regulation of FoxM1 expression in cancer cells.39 Overexpression of epidermal growth factor receptor pathway substrate 8 induces FoxM1 expression in cancer cells through PI3K activation. However, the specific PI3K isoform was never identified. The present study provide clear evidence that FoxM1 is induced in the pulmonary vasculature in a p110γ-dependent manner following inflammatory vascular injury. Our studies demonstrate the GPCR agonist SDF-1α is a critical upstream activator of the GPCR-dependent PI3K isoform p110γ in human lung ECs. Activation of p110γ results in FoxO1 nuclear export and inactivation and thereby induction of FoxM1 expression. We observed that inhibition of FoxO1 reversed p110γ-inhibition-mediated blockade of SDF-1α-induced FoxM1 expression whereas inhibition of FoxO1 nuclear export, i.e. activation of FoxO1 inhibited SDF-1α-induced FoxM1 expression in ECs. Importantly, SDF-1α is induced in mouse lungs only in the recovery phase following LPS challenge. A recent study shows that p110γ cooperating with the class II PI3K-C2β plays a role in sphingosine-1-phosphate-induced EC migration.40 However, we observed no induction of FoxM1 expression in ECs by sphingosine-1-phosphate. Thus, sphingosine-1-phosphate is not the upstream activator of p110γ to activate FoxM1-dependent endothelial regeneration. Taken together, our data suggest an important role of SDF-1α signaling in activating the GPCR-dependent p110γ PI3K and thereby promoting FoxM1-dependent endothelial regeneration and vascular repair.
p110γ, which is highly expressed in hematopoietic cells,41 regulates the early phase of transendothelial leukocyte migration occurring within minutes to hours.42,43 Consistently, we also observed an early (2h post-LPS) decrease of neutrophil infiltration in Pik3cg−/− mouse lungs. However, the subsequent neutrophil uptake in Pik3cg−/− mouse lungs (up to 24h post-LPS) was the same as in WT lungs. This increase paralleled the vascular permeability values at this time in both groups. At 48h and 72h post-LPS, the increases in neutrophil uptake persisted in Pik3cg−/− mouse lungs in which vascular permeability was also increased, whereas neutrophil uptake was restored to basal level in WT mouse lungs in which permeability had fully recovered. Restoring the expression of either p110γ or FoxM1 in ECs of Pik3cg−/− mouse lungs fully normalized vascular repair and resolved lung inflammation. Given that FoxM1 is essential for endothelial regeneration,11 the impaired resolution of lung inflammation in Pik3cg−/− mouse lungs is likely the result of failure of vascular integrity to recover in these lungs. In support of the concept that recovery of endothelial barrier function is required to resolve lung inflammation, studies have shown strong causal relationship between leakiness of the microvessel barrier and transendothelial migration of neutrophils.2,44,45 Additionally, we observed elevated mRNA levels of ICAM-1, iNOS and various pro-inflammatory mediators (TNFα and IL-6) in Pik3cg−/− mouse lungs at 48h post-LPS in contrast to Pg−/−/Tg mouse lungs. Since these pro-inflammatory pathways are not the direct transcriptional targets of FoxM1, it is unlikely that the persistent lung inflammation seen in Pik3cg−/− mouse lungs was the result of activation of these pathways. Our results support the essential role of impaired p110γ-FoxM1 signaling as being responsible for the defective vascular repair and thereby impaired resolution of inflammation.
Employing the mouse model of ALI induced by intratracheal instillation of LPS, Kim et al. observed decreased lung inflammation and vascular permeability in mice pretreated with p110γ inhibitor AS605240.46 The discrepancy of this observation with ours may ascribe to the different models of lung injury. In contrast to systemic administration of LPS which induces systemic inflammation and multiple organ injury, intratracheal instillation of LPS-induced injury is limited in the lung. As p110γ plays a critical role in neutrophil recruitment and migration, pretreatment with AS605240 to inhibit p110γ impairs neutrophil infiltration into the lung and thus may result in reduced lung inflammation and vascular injury in the lung injury model induced by intratracheal instillation of LPS. Consistent with the findings in LPS-induced endotoxemia, we also observed that p110γ deficiency impairs endothelial regeneration and induces persistent lung vascular injury and sustained lung inflammation as well as increased mortality following CLP-induced polymicrobial sepsis. In agreement with our observation, previous studies have shown that PI3K signaling plays an important protective role in the response to polymicrobial sepsis.47,48 Inhibition of PI3K with pan-PI3K inhibitors (wortmannin or LY294002) results in increased susceptibility to polymicrobial sepsis in CLP mice and induced a marked increase of mortality.47,48 In a separate report, Maus, et al. observed increased lung injury and mortality of Pik3cg−/− mice following pneumococcal infection.49 However, Martin, et al. demonstrates that p110γ deficiency or p110γ inhibition reduces multiorgan damage and improves survival.50 In the present study, we showed that p110γ was indispensible for endothelial regeneration and vascular repair following injury induced by endotoxemia and polymicrobial sepsis. Our studies for the first time have identified FoxM1 as the critical downstream effector of endothelial p110γ. We have shown that transgenic expression of FoxM1 normalizes vascular repair and reduces CLP-induced mortality. Importantly, we also observed decreased p110γ expression in the pulmonary vascular ECs of ARDS patients, supporting the concept that impaired p110γ-FoxM1 endothelial regeneration signaling pathway is a critical factor in persistent leaky lung microvessels and edema formation in the disease.
In summary, our studies provide unequivocal evidence that endothelial p110γ is required for FoxM1 expression in ECs in vivo and thereby mediates the endothelial regeneration and vascular repair program following sepsis-induced inflammatory vascular injury. Our data also showed decreased expression of p110γ in pulmonary vascular ECs of ARDS patients. Thus, activation of p110γ signaling may represent a novel therapeutic strategy for restoring vascular integrity and resolving lung inflammation associated with ALI/ARDS.
The integrity of endothelial monolayer is essential for vascular homeostasis. However, little is known about the signaling pathways regulating regeneration of the endothelial barrier following inflammatory vascular injury. In this study, we have identified a novel function of p110γPI3K expressed in ECs in mediating endothelial regeneration and vascular repair. We showed that endothelial p110γ activation by GPCR signaling following sepsis-induced vascular injury was required for FoxM1 activation and the resulting repair of the endothelial barrier and resolution of inflammation. Our data also provide evidence of the clear association of ARDS with diminished expression of p110γPI3K in pulmonary vascular ECs of ARDS patients. Thus, development of means of activation of p110γPI3k-FoxM1 signaling may represent a novel strategy for treatment of inflammatory vascular diseases such as ALI/ARDS.
We thank Dr. Philippe Huber from the Department of Cellular Responses and Dynamics, CEA-INSERM-Joseph Fourier University, France for his generosity of providing the human CDH5 promoter and Dr. Robert G. Kalb from the Department of Neurology, University of Pennsylvania for providing FoxO1 nuclear export inhibitor psammaphysene A.
Funding Sources: This work was supported in part by NIH grants R01HL123957, R01HL125350, and P01HL077806 (Project 3) to Y.Y.Z.